Recombinant Dengue Virus Serotype 2 VLP

• Cat.No.: VLP-02D
• Product Overview: Recombinant Dengue Virus serotype 2 virus-like particle recombinant antigen consisting of Envelope, pre-Membrane and Membrane protein produced in 293 human cells. The C terminal 20% of the dengue Envelope protein was replaced by the corresponding Japanese encephalitisvirus SA-14 sequence (Envelope protein amino acids 397-495). The replaced sequence corresponds to the transmembrane and intraparticle portion of the protein.
  Strain/Isolate: Thailand/16681/84

Specification

• Description: Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.
• Source: HEK293
• Species: Dengue Virus Serotype 2
• Form: Liquid
• Purity: >95% pure by SDS-PAGE
• Stability: At +4 centigrade: 1 week
  At -80 centigrade: 1 year
  Avoid excessive mixing or shocking to prevent aggregation. Long term storage above -80 centigrade may result in aggregate formation.
  Can be frozen, but avoid multiple freeze/thaw cycles.
• Storage: Short Term Storage: +4 centigrade
  Long Term Storage: -80 centigrade
• Storage Buffer: 10mM sodium phosphate, 20mM sodium citrate, 154mM sodium chloride, pH7.4.
• Shipping: Dry ice.
• Synonyms: VLP; virus-like particles

Gene Information

• Synonyms: VLP; virus-like particles